AzTrials
AzTrials

Parkinson DiseaseNCT04769973

Treatment Burden in Parkinson's

An observational study of Parkinson Disease and Parkinson, run by University of Southampton at 2 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: People with Parkinson's (PwP) have many symptoms including tremor, stiffness, slow movements, constipation, urinary incontinence and mental health issues. They are often older and have other long-term health conditions. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Parkinson Disease, Parkinson
How many people
188 participants
Where
2 sitesUnited Kingdom
Study dates
22 Jun 2021to 2 Aug 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 1. Participants for the interviews will be purposively sampled from Parkinson's clinics in Hampshire and Dorset. 2. Participants for the national survey will be recruited from Parkinson's clinics in Hampshire and Dorset as well as through Parkinson's UK Research Support Network and Take Part Hub. 3. Participants for the focus groups will be recruited from Parkinson's clinics in Hampshire and Dorset as well as working with Wessex Parkinson's Excellence Network

Who may be able to join

  • People diagnosed with Parkinson's or caregiver of someone diagnosed with Parkinson's
  • Able to consent to participate
  • Have a role in the care of someone with Parkinson's including but not limited to people diagnosed with Parkinson's, caregiver of someone with diagnosed with Parkinson's, healthcare professionals, volunteer sector representative, policy maker or manager
  • Able to consent to participate.

Who cannot join

  • 1. Unable to consent to participate
  • For Work Package 3:
  • 1. Unable to consent to participate

Trial locations and contacts

2 sites in 1 country.

United Kingdom2 sites
  • Christchurch Hospital, University Hospitals Dorset NHS Foundation Trust

    Bournemouth, Dorset, Bh23 2JX

  • Romsey Hospital, Southern Health NHS Foundation Trust

    Southampton, Hampshire, SO51 7ZA

Other trials in United Kingdom

About this study

Official title: The PD Life Study: Exploring the Treatment Burden and Capacity of People With Parkinson's and Caregivers

Background:

People with Parkinson's (PwP) have many symptoms including tremor, stiffness, slow movements, constipation, urinary incontinence and mental health issues. They are often older and have other long-term health conditions. PwP need to do many things to look after their health including manage multiple medications, attend healthcare appointments and lifestyle changes such as improving diet and exercise.

Read more

The effort of looking after their health and its impact on them is termed 'treatment burden'. Some PwP need help from their family or friends (caregiver) to complete these tasks. Caregivers may also experience treatment burden themselves when caring for someone with Parkinson's. People's ability to manage treatment burden is termed 'capacity' and is influenced by physical, mental, social and economic factors. People are overburdened when the workload of looking after their health exceeds their capacity. This can lead to poor adherence with treatment, poor quality of life and worse health outcomes.

Aim:

To understand the factors that influence treatment burden and capacity in PwP and caregivers of PwP.

Methods:

Interviews with PwP and caregivers will identify factors that influence treatment burden and capacity. These factors will be explored further in a national survey for PwP and caregivers through Parkinson's UK. The investigators will form focus groups with PwP, caregivers, voluntary sector representatives, healthcare professionals, policy makers and managers through Parkinson's Excellence Networks to discuss and prioritise recommendations for change.

Outcomes:

The investigators will disseminate recommendations of ways to reduce treatment burden and improve future experiences of PwP and caregivers.

Read the detailed description

This is a mixed-methods study that will be conducted over three work packages as described below and will be completed in 24 months. The investigators will have patient and public involvement throughout the study.

Work Package 1 - Interviews:

The investigators will interview 15-20 PwP and 15-20 caregivers (face-to-face, telephone or video calls) recruited from Parkinson's clinics in Hampshire and Dorset to identify factors that influence treatment burden and capacity among PwP and caregivers of PwP. Participants will be eligible to take part in the study if they have a diagnosis of Parkinson's or is a caregiver for someone with Parkinson's, and able to give informed consent. The investigators will use purposive sampling to include both genders, a range of ages, severity of Parkinson's and caregiver relationships. Potential eligible participants will be identified by the clinical team. Written consent will be obtained prior to each interview. Interviews will be audio-recorded and transcribed. The investigators will take an inductive approach to identify emerging themes until no new information arises.

Work Package 2 - National Survey:

Results from the interviews will then inform the development of a national survey for PwP and caregivers. The national survey will for the first time quantify treatment burden using the Multimorbidity Treatment Burden Questionnaire (MTBQ) and capture aspects of capacity such as severity and duration of Parkinson's, social and economic resources, medications, frailty and health literacy. Participants with mild, moderate and severe Parkinson's will be recruited with agreed support from Parkinson's UK and from Parkinson's clinics. Participants will be eligible to take part in the study if they have a diagnosis of Parkinson's or is a caregiver for someone with Parkinson's, and able to give informed consent. Each participant will be able to complete a separate survey online or on paper.

The investigators will collect the following data from participants:

  1. Sociodemographic data: age, sex, ethnicity, cohabitation status, living situation, presence of caregiver, employment status, education level, access and ability to drive, access to information technology
  2. Multimorbidity Treatment Burden Questionnaire (MTBQ
  3. Information about Parkinson's including: - i) Year of diagnosis ii) Self-reported Parkinson's severity (Hoehn and Yahr)
  4. Other health conditions
  5. Single-item health literacy score
  6. Medications use and frequency
  7. Healthcare use of the person with Parkinson's in the last 12 months e.g. primary, secondary and urgent care
  8. Assessment of frailty with PRISMA-7: a brief 7-item self-reported questionnaire
  9. Quality of Life Measures with the 12-item Short Form Health Survey (SF-12v2)
  10. A single question to consider the overall effort of looking after health

The investigators will also collect data regarding non-motor symptoms from PwP using the Parkinson's Disease Non-Motor Symptoms Questionnaire.

The investigators will collect the following data from caregivers of PwP: -

  1. Information about the Parkinson's of the person they care for including: - i) Issues with memory, mood and hallucinations ii) Awareness of deterioration from the person with Parkinson's
  2. Zarit Burden Interview: a 12-item scale that assesses the caregiver burden.

Work Package 3 - Focus groups and Dissemination:

Working with Wessex Parkinson's Excellence Network, the investigators will hold two to four focus groups with key stakeholders including PwP, caregivers, voluntary sector representatives, healthcare professionals, policy makers and managers. Participants will be recruited from each local area (Hampshire and Dorset) through Parkinson's clinics, support groups and local services depending on the findings from the interviews and surveys. Each focus group will have 6-10 participants and will be moderated by a member of the research team. Written consent will be obtained from each participant prior to the focus group. Focus groups will be conducted either face-to-face at a neutral location or conducted via video call. Each focus groups will be audio-recorded using a digital recorder with consent and transcribed for further data analysis. The focus groups will discuss the overall study findings and aim to develop and prioritise recommendations of ways to reduce treatment burden and enhance capacity among PwP and their caregivers.

The investigators will then hold a dissemination event to share the outcomes with people affected by Parkinson's with support from Parkinson's UK and the Academic Health Science Networks. The investigators will work closely with Parkinson's UK Excellence Networks to share knowledge and implement changes that improve treatment burden and enhance capacity among PwP and caregivers. The findings will be disseminated through publications in peer-reviewed journals and presentations at regional and national conferences.

Keywords
Treatment Burden, Burden of Treatment
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04769973
Study groupRoleWhat they receive
Work Packages 1 - 3Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers. Work Package 2: National Survey with up to 2000 participants Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment Burden Experiences

    The investigators will describe the key factors that influence participants' experiences of treatment burden

    Measured: 24 months

  2. Capacity

    The investigators will describe the key factors that influence participants' capacity

    Measured: 24 months

  3. Treatment Burden Levels

    Treatment burden levels will be measured using the Multimorbidity Treatment Burden Questionnaire (MTBQ):- Overall scores (0-100) categorised as no burden (score 0), low burden (score <10), medium burden (10-22) and high burden (>=22).

    Measured: 24 months

Secondary outcomes (3)
  1. Multimorbidity and treatment burden levels

    Multimorbidity assessed with self-reported number of co-morbidities

    Measured: 24 months

  2. Frailty and treatment burden levels

    Frailty assessed using the Program of Research to Integrate Services for the Maintenance of Autonomy (PRISMA-7) screening tool; Score of ≥3 defined as frail

    Measured: 24 months

  3. Severity of Parkinson's and treatment burden levels

    Severity Parkinson's will be measured using the self-reported Hoehn and Yahr scale (0-5) 0 - No sign of disease

    1. - Unilateral involvement
    2. - Bilateral involvement without impairment of balance
    3. - Mild to moderate bilateral disease; some postural instability; physically independent
    4. - Severe disability; still able to walk or stand unassisted
    5. - Wheelchair bound or bedridden unless aided

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2021
  2. Study start22 Jun 2021
  3. Primary completion2 Aug 2022
  4. Study completion2 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
188 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04769973
Sponsor's protocol ID
62623
Other IDs
277464
Status last verified
Nov 2022
First submitted
15 Jan 2021
Last updated
14 Nov 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymised study data will be made available upon request.

Questions about this trial

What is this clinical trial studying?

An observational study of Parkinson Disease and Parkinson, run by University of Southampton at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment Burden Experiences (time frame: 24 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2022; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in